Archive for the ‘Crispr’ Category

Just because you've watched Jurassic Park doesn't mean you know that gene editing is bad

COURTESY OF FLICKR

Gene editing is an important area for further research.

Gene editing is the future and we should embrace it. I dont mean a wholehearted approval of the technique but to recognize that its here. We must be thoughtful about its applications and aware of its potential.

Weve been gene editing all throughout history. Selectively breeding animals and crops to promote the traits that are desirable or helpful to us. But todays gene editing is much different.

We use CRISPR-Cas9, which can target specific gene sequences to edit, said Samantha Noll, a bioethicist with the Functional Genomics Initiative.

CRISPR, a gene editing tool taken from bacterial defenses against viruses, allows molecular biologists here at WSU to alter specific genes in big animals. Compared to CRISPR, selective breeding is crude and inaccurate, only using phenotypic traits, such as eye or hair color, as the roadmap for which animal to breed or not. Selective breeding attempts to manipulate the genome by prioritizing expressed traits whereas CRISPR allows the manipulation of the genome by access to the entire gene pool.

Charlie Powell, the public information officer for WSUs school of Veterinary Medicine, mentioned multiple ways this gene editing technique can be applied positively.

At any given moment here in the US there are a million pigs in transit. A certain percentage of those animals will develop upper respiratory diseases as a result of the stress, Powell said. If we could make those pigs resistant instead of vaccinating them then we have the possibility of limiting those losses in the industry. This involves adding back the wild-type genes that they originated with.

This suggests ethical solutions by way of medical intervention. Lingering just on livestock application, how much animal suffering could be eliminated by well-applied selective gene editing? Instead of injecting tons of antibiotics, genetic immunity may be the way to go.

Fostering the path to healthier and happier livestock could be inroads to alleviating human challenges such as hunger and poverty. Abundance of sustainable and ethically produced meats could ease food demand, and resilient healthy livestock could be a valuable investment for underprivileged individuals.

Being a land-grant university, WSU research is primarily aimed at helping the local community, hence the focus on big animals and local agriculture. One of the research programs seeks to knock out the genes responsible for horns in cattle. This avoids the painful horn removal process for the animals and prevents accidental injury between cattle, which cost time and money.

Though these are promising initiatives, we cant be short-sighted either. William Kabasenche, a bioethicist focusing on the therapeutic applications of CRISPR, described what he called off-target effects.

Its called pleiotropy, when one gene influences multiple phenotypes, Kabasenche said.

Phenotypes are just the expressed traits. The information for those traits is stored in the gene. Off-target effects occur when a gene has unaccounted phenotypes, meaning that the manipulation of that gene produced an unforeseen or undesirable change in a phenotype.

This is why we have to be very careful when gene editing. Yes, the potential is huge both for scientific discovery as well as the well-being of conscious entities but we must guard against a utopic vision of the technology. There are trade-offs involved. Changing one gene may produce the desired effects, but drastically impact an unrelated but necessary function.

This stresses the need for research and the role of ethics in research. We should all want this work to be done, but we cannot simply focus on positive outcomes and draw the conclusion that it justifies its good. We must also consider how these outcomes are achieved.

We must also consider the harmful potential of gene editing. How we choose to engage our resources, the decisions and norms we set in research will in some part determine how well apply this technology. These norms are being born at research institutions like WSU.

Its a promising start that WSU includes ethicists, educators and biologists to tackle these difficult issues.

See the original post:
OPINION: Support gene researchers - The Daily Evergreen

Chicago, United States: The global CRISPR Technology Market is expected to surge at a steady CAGR in the coming years, states the latest Report Hive Research. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global CRISPR Technology market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global CRISPR Technology market.

The CRISPR Technology market study published in the report is in a chapter-wise format to ease of the readability and complexity of the data covered. Each chapter is further categorized into its respective segments containing well-structured data. The competitive scenario displayed includes major market player details such as, company profile, end-user demand, import/export volume, sales data, etc. The report also covers the business strategies applied by different players, which will be a great addition for smart business decisions.

Get a Sample PDF Report: https://www.reporthive.com/request_sample/2243315

Top Key players cited in the report:

Thermo Fisher ScientificMerck KGaAGenScriptIntegrated DNA Technologies (IDT)Horizon Discovery GroupAgilent TechnologiesCellecta, Inc.GeneCopoeia, Inc.New England BiolabsOrigene Technologies, Inc.Synthego CorporationToolgen, Inc.

In this report, we analyze the CRISPR Technology industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2020 to 2025. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2020 to 2025. We also make a prediction of its production and consumption in coming 2019-2024.At the same time, we classify different CRISPR Technology based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What is more, the CRISPR Technology industry development trends and marketing channels are analyzed.

The research report is committed to giving its readers an unbiased point of view of the global CRISPR Technology market. Thus, along with statistics, it includes opinions and recommendation of market experts. This allows the readers to acquire a holistic view of the global market and the segments therein. The research report includes the study of the market segments on the basis of type, application, and region. This helps in identifying segment-specific drivers, restraints, threats, and opportunities.

The scope of the Report:The research report on the global CRISPR Technology market is a comprehensive publication that aims to identify the financial outlook of the market. For the same reason it offers a detailed understanding of the competitive landscape. It studies some of the leading players, their management styles, their research and development statuses, and their expansion strategies.

The report also includes product portfolios and the list of products in the pipeline. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Global CRISPR Technology Market: Competitive RivalryThe chapter on company profiles studies the various companies operating in the global CRISPR Technology market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the CRISPR Technology market participants in the past few years to remain ahead of the competition.

Global CRISPR Technology Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global CRISPR Technology market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global CRISPR Technology market.

CRISPR Technology Segmentation by Product

EnzymesKitsgRNALibrariesDesign Tools

CRISPR Technology Segmentation by Application

BiomedicalAgricultural

Get Customized PDF template of this report: https://www.reporthive.com/request_customization/2243315

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global CRISPR Technology market

Chapter 2: Evaluating the leading manufacturers of the global CRISPR Technology marketwhich consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global CRISPR Technology marketby regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Speak to Research Analyst: +1-312-604-7084

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

The rest is here:
CRISPR Technology Market 2020 Sales and Revenue Analysis by Region, 2020-2025 | Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA...

One key to stopping the spread of Covid-19 is knowing who has it. A delay in reliable tests and Covid-19 diagnostics in the United States has painted an unreliable picture of just how many people are infected and how the epidemic is evolving. But new testing options are now becoming available and the information from these diagnostics will help guide decisions and actions important for public health.

McGovern Institute research scientists Omar Abuddayeh and Jonathan Gootenberg have been developing CRISPR technologies to rapidly diagnose Covid-19 and other infectious diseases. They recently described the current state of Covid-19 testing.

Q: How do Covid-19 tests work?

A: There are three main types of tests. The first uses the detection of nucleic acid. These tests directly test for the RNA genome of the virus in a variety of sample types, such as nasopharyngeal swabs or sputum. These tests are most commonly performed using polymerase chain reaction (PCR), which can amplify a small part of the virus RNA sequence billions-of-fold higher to allow detection with a fluorescence measuring instrument. These types of tests are highly sensitive, allowing for early detection of the virus days after infection. PCR tests require complex instrumentation and are usually performed by skilled personnel in an advanced laboratory setting. An alternative method is SHERLOCK, a nucleic acid-based test developed here at MIT stemming from the CRISPR gene editing tool that does not need complex instrumentation and can be read out using a paper strip akin to a pregnancy test, without any loss of sensitivity or specificity. The test is also low-cost and can be performed in less than an hour. Because of these features, we are hoping to gain FDA approval that allows deployment at the point of care or at home testing with our Covid-19 SHERLOCK test kit.

The second type of Covid-19 test detects viral proteins. Some tests use a paper strip that have antibodies against Covid-19 proteins. These allow for easy detection of the virus in less than an hour but are at least a million-fold less sensitive than nucleic acid-based tests because there is no amplification step. This makes them less ideal for screening purposes, as many patients will not have enough viral load in sputum or swabs and will receive false negative results.

The third category is serology tests that detect antibodies against the virus. These tests can also be used as a paper strip with antibodies that detect other antibodies that develop in someones blood in response to Covid-19 infection. Antibodies do not show up in blood until one to two weeks after symptoms present, so these tests are not great for catching infection at early stages. Serology tests are more useful for determining if someone has had the infection, recovered, and developed immunity. They may serve a purpose for finding immune people and deciding whether they can go back to work, or for developing antibody-based therapies.

Q: Why arent there more Covid-19 tests available?

A: The difficulties in getting nucleic acid detection tests stem from a confluence of multiple factors, including limited supplies of tests, limited supplies of other consumables needed for testing (such as nasal swabs or RNA purification kits), insufficient testing bandwidth at sites that can perform tests (often due to bottlenecks in labor or instruments), and complications behind the logistics of assigning tests or reporting back results. As a result, just producing more testing material would not solve the issue outright, and either more instrumentation and labor is required, or newer, more rapid tests need to be developed that can be performed in a more distributed manner with reduced dependence on equipment, centralized labs, or RNA purification kits.

Q: What kind of Covid-19 test are you developing now?

A: We are working on a nucleic acid-based test that does not require complex instrumentation, rapidly returns results (with a goal of under one hour), and can be performed at a point-of-care location without trained professionals. We hope to accomplish this using a combination of techniques. First, we are incorporating isothermal amplification technologies, which, unlike current PCR-based tests, do not require intricate heating and cooling to operate. We are combining this with our CRISPR-based diagnostics, allowing for sensitive detection and readout in a simple visual format, akin to a pregnancy test. We hope that this test will significantly lower the barrier for accurate diagnosis and provide another approach for Covid-19 surveillance.

Excerpt from:
3 Questions: How Covid-19 tests work and why they're in short supply - MIT News

Base editors, which convert one nucleotide to another without a double-strand DNA break, have the potential to treat diseases caused by mutant genes. One drawback, though, is that the DNA that encodes CRISPR base editors is longtoo long to fit in the adeno-associated viruses (AAVs) most commonly used for gene therapy. In a study published in Molecular Therapy on January 13, researchers split the DNA encoding a base editor into two AAV vectors and injected them into a mouse model of inherited amyotrophic lateral sclerosis (ALS). The strategy disabled the disease-causing gene, improving the animals symptoms and prolonging their lives.

Wed like to be able to make gene editing tools that can fit inside an AAV vector. Unfortunately, some of the tools are so big that they cant fit inside, so in this study, they were able to come up with a solution to that by using a split protein, says David Segal, a biochemist at the University of California, Davis, who was not involved in the work. Its not the first time that that system has been used, but its the first time its been applied to this kind of base editor.

Pablo Perez-Pinera, a bioengineer at University of Illinois at Urbana-Champaign, and colleagues developed a strategy to split the base editor into two chunks. In a study published in 2019, they generated two different AAV vectors, each containing a portion of coding DNA for an adenine-to-thymine base editor. They also included sequences encoding so-called inteinsshort peptides that when they are expressed within proteins stick together and cleave themselves out, a bit like introns in RNA. The researchers built the inteins into the vectors such that when the inteins produced by the two vectors dimerized, bringing the two base editor parts together, and then excised themselves, they left behind a full-length, functional base editor.

When Perez-Pinera told Thomas Gaj, also a bioengineer at the University of Illinois at Urbana-Champaign, about the strategy, Gaj tells The Scientist,they immediately set out to test it in a mouse model of ALS. The transgenic mice have about 25 copies of the human gene, superoxide dismutase 1(SOD1), with mutations that cause ALS in people. The animals display motor neuron loss and muscle atrophy, plus their neurons accumulate inclusionsdense spots in the gray and white matter of their spinal cords that include SOD1 proteinbefore dying at about four months of age on average. The symptoms and life expectancy in the 20 percent of ALS patients with mutations in SOD1vary based on which mutation they have, but most have muscle weakness and motor neuron death, as well as inclusions containing SOD1 protein.

Instead of using the adenine-to-thymine base editor, the researchers developed a cytosine-to-thymine converter using the coding sequence of Streptococcus pyogenes Cas9 and a guide RNA that targets both wild type and mutant human SOD1 to create an early stop codon. This doesnt affect the mouse SOD1. In human cells, the split base editor seemed to be even more efficient than when the editor was transfected at full length, hitting about 29 percent of the target sites, compared to the full-length editors 19 percent.

Next the authors packaged their split base editor into two AAV backbones and injected them or a control AAV into the animals lumbar cerebrospinal fluid when they were around two months old. The vectors ended up primarily in astrocytes, as well as in neurons and microglia. While the researchers didnt see a difference in symptom onset at around three months, the mice that received the base editor maintained their weight and lived about 10 percent longer than controls. The treated mice also had fewer SOD1-positive inclusions and healthier motor neurons.

In this cross section of the spinal cord of a mouse model of amyotrophic lateral sclerosis (ALS), researchers delivered a CRISPR base editing system (yellow) to astrocytes (red) in order to disable the expression of a mutant gene and reduce symptoms.

Colin Lim, University of Illinois

Using base editors to disable the mutant SOD1 gene in astrocytes (a cell type that normally supports healthy nervous system function but in SOD1-ALS exerts toxicity onto motor neurons) led to a marked slowing in disease progression, Gaj writes in an email to The Scientist. Since many persons with ALS are diagnosed following the onset of symptoms, pre-clinical strategies that can meaningfully slow the disease are especially important and should be further studied.

This is a good indication that base editing actually can be used to treat ALS, says Baisong Lu, a gene therapy researcher at Wake Forest School of Medicine who did not participate in the work. He cautions that off-target effectsthe base editor can edit both DNA and RNAand how long the AAV delivery method lasts are both in need of more work before this technique would be safe for people.

The dual AAV strategy could also be expensive, says Mimoun Azzouz, a neuroscientist at the University of Sheffield in the United Kingdom. Thinking about the clinical development and marketing and the commercialization of this product, you need to manufacture two viruses, and you need to assess these two viruses for safety, so the cost can be extremely high.

Despite the challenges, the strategy shows promise for translation to humans, Perez-Pinera writes in an email to The Scientist.AAVs are already approved by the Food and Drug Administration for gene therapy, he explains. Plus, using a humanized model of the diseasea mouse that contains the human sequence of the target genemeans that the method validated in mouse models can be translated to people without adapting them to target a different sequence. People who develop ALS due to a mutation in SOD1also have one good copy of the gene, just like the mice, which have a functioning mouse copy.

We injected animal models shortly before disease onset. While injecting the animals earlier could improve the outcome of the disease as demonstrated in other studies, the reality is that ALS is not typically diagnosed until the patient experiences symptoms. Our study predicts what can be expected from treating a patient recently diagnosed with the disease, Perez-Pinera writes.

We still have some distance to travel before the results in our current study can benefit ALS patients, Gaj acknowledges. The researchers are working on minimizing off target effects and on developing new delivery methods that could improve efficacy. We still have a number of important questions to answer and technological hurdles to address before we begin thinking about clinical translation.

C.K.W. Lim et al., Treatment of a mouse model of ALS by in vivo base editing,Molecular Therapy,doi:10.1016/ j.ymthe.2020.01.005, 2020.

Abby Olena is a freelance journalist based in Alabama. Find her on Twitter@abbyolena.

Read this article:
Symptoms in ALS Mouse Model Improve with CRISPR Base Editing - The Scientist

CRISPR And CRISPR-Associated (Cas) Genes Market Forecast 2020-2026

The Global CRISPR And CRISPR-Associated (Cas) Genes Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the CRISPR And CRISPR-Associated (Cas) Genes Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://industrygrowthinsights.com/request-sample/?reportId=171631

The Report Covers the Following Companies:Caribou BiosciencesAddgeneCRISPR THERAPEUTICSMerck KGaAMirus Bio LLCEditas MedicineTakara Bio USAThermo Fisher ScientificHorizon Discovery GroupIntellia TherapeuticsGE Healthcare Dharmacon

By Types:Genome EditingGenetic engineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering

By Applications:Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://industrygrowthinsights.com/ask-for-discount/?reportId=171631

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about CRISPR And CRISPR-Associated (Cas) Genes Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=171631

About Industrygrowthinsights:Industrygrowthinsights has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://Industrygrowthinsights.com

See the original post:
CRISPR And CRISPR-Associated (Cas) Genes Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications - Science In Me

This detailed research report on the Global CRISPR Technology Market offers a concrete and thorough assorted compilation of systematic analysis, synthesis, and interpretation of data gathered about the CRISPR Technology Market from a range of diverse arrangement of reliable sources and data gathering points. The report provides a broad segmentation of the market by categorizing the market into application, type, and geographical regions.

In addition, the information has analysed with the help of primary as well as secondary research methodologies to offer a holistic view of the target market. Likewise, the CRISPR Technology Market report offers an in-house analysis of global economic conditions and related economic factors and indicators to evaluate their impact on the CRISPR Technology Market historically.

This study covers following key players:

Thermo Fisher ScientificMerck KGaAGenScriptIntegrated DNA Technologies (IDT)Horizon Discovery GroupAgilent TechnologiesCellectaGeneCopoeiaNew England BiolabsOrigene TechnologiesSynthego CorporationToolgen

Request a sample of this report @ https://www.orbismarketreports.com/sample-request/66342?utm_source=Puja

The report is a mindful assortment of vital factors that lend versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global CRISPR Technology Market. This detailed report on CRISPR Technology Market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. All the notable CRISPR Technology Market specific dimensions are studied and analysed at length in the report to arrive at conclusive insights. Apart from highlighting these vital realms, the report also includes critical understanding on notable developments and growth estimation across regions at a global context in this report on CRISPR Technology Market.

Besides these aforementioned factors and attributes of the CRISPR Technology Market, this report specifically decodes notable findings and concludes on innumerable factors and growth stimulating decisions that make this CRISPR Technology Market a highly profitable. A thorough take on essential elements such as drivers, threats, challenges, opportunities are thoroughly assessed and analysed to arrive at logical conclusions. Additionally, a dedicated section on regional overview of the CRISPR Technology Market is also included in the report to identify lucrative growth hubs. These leading players are analysed at length, complete with their product portfolio and company profiles to decipher crucial market findings.

Access Complete Report @ https://www.orbismarketreports.com/global-crispr-technology-market-size-status-and-forecast-2019-2025?utm_source=Puja

Market segment by Type, the product can be split into

EnzymesKitsgRNALibrariesDesign Tools

Market segment by Application, split into

BiomedicalAgricultural

The report also lists ample correspondence about significant analytical practices and industry specific documentation such as SWOT and PESTEL analysis to guide optimum profits in CRISPR Technology Market. In addition to all of these detailed CRISPR Technology Market specific developments, the report sheds light on dynamic segmentation based on which CRISPR Technology Market has been systematically split into prominent segments encompassing type, application, technology, as well as region specific segmentation of the CRISPR Technology Market.

Some Major TOC Points:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and ApplicationContinued

For Enquiry before buying report @ https://www.orbismarketreports.com/enquiry-before-buying/66342?utm_source=Puja

About Us :

With unfailing market gauging skills, has been excelling in curating tailored business intelligence data across industry verticals. Constantly thriving to expand our skill development, our strength lies in dedicated intellectuals with dynamic problem solving intent, ever willing to mold boundaries to scale heights in market interpretation.

Contact Us :

Hector Costello

Senior Manager Client Engagements

4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.

Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Read more:
Global CRISPR Technology Market Study Along With Business Ideas, Development Trends and Key Segments Till 2025 : Thermo Fisher Scientific, Merck KGaA,...

The global CRISPR and CAS Gene Market research report thoroughly explains each and every aspect related to the CRISPR and CAS Gene Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. The growth trend forecasted on account of thorough examination offers in-depth information regarding the global CRISPR and CAS Gene Market. A pathway of development is offered by the market to the several connected networks of businesses under it, which include different firms, industries, organizations, vendors, distributors, and local manufacturers too. All the key CRISPR and CAS Gene Market players compete with each other by offering better products and services at a reasonable price in order to grab significant share at the regional and global level market.

CRISPR technology is a simple yet powerful nucleic acid-targeting editing tools for genome. It allows researchers to easily alter DNA sequences and modify gene function. It has many potential applications, which include correcting genetic defects, treating and preventing the spread of diseases, and improving crops

Get a Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2598

The report incorporates an estimated impact of strict standards and regulations set by the government over the market in the upcoming years. The market report also comprises exhaustive research done using several analytical tools such as SWOT analysis to identify the market growth pattern.

Top Manufactures in GlobalCRISPR and CAS GeneMarket Includes:Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Regions & Countries Mentioned In The CRISPR and CAS Gene Market Report:

North America ( United States)

Europe ( Germany, France, UK)

Asia-Pacific ( China, Japan, India)

Latin America ( Brazil)

The Middle East & Africa

Key Highlights of the Table of Contents:

CRISPR and CAS Gene Market Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global market, years considered, and study objectives. Furthermore, it tuches the segmentation study provided in the report on the basis of the type of product and applications.

CRISPR and CAS Gene Market Executive Summary: This section emphasizes on the key studies, market growth rate,Competitive landscape, market drivers, trends, and issues.

CRISPR and CAS Gene Market Production by Region: The report provides information related to import and export, production, revenue, and key players of all regional markets studied are covered in this section.

CRISPR and CAS Gene Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2598

Table of Contents

Report Overview:It includes the CRISPR and CAS Gene market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about CRISPR and CAS Gene market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the CRISPR and CAS Gene market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the CRISPR and CAS Gene market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Access insightful study with over 100+ pages, list of tables & figures, profiling 10+ companies https://www.coherentmarketinsights.com/insight/request-pdf/2598

About CMI:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154,U.SPhone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

Read more from the original source:
Latest Update 2020: CRISPR and CAS Gene Market By Covid19 Impact Analysis And Top Manufacturers: Caribou Biosciences Inc., CRISPR Therapeutics, Mirus...

CRISPR Therapeutics AG (CRSP) stock traded 746576 shares in most recent trading session as compared to an average volume of 1.05M shares. It shows that the shares were traded in the recent trading session and traders shown interest in CRSP stock. Shares of the CRISPR Therapeutics AG (CRSP) moved up 7.08% to trade at $42.17 in Monday trading session. It has a market capitalization of $2.57B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock P/E & is 43.43 & EPS is $0.97 against its recent stock value of $42.17 per share.

First we will be looking for the boiling points and excitability of CRISPR Therapeutics AG (CRSP) stock, it purposes common trait for traders and value investors.

Volatility Indicators for CRISPR Therapeutics AG:

Volatility of the CRISPR Therapeutics AG remained at 6.73% over last week and shows 10.18% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 3.94. Beta value is also an important factor that helps to know how much the Market risk lies with the trading of subjective stock. Beta indicator of this stock lies at 2.52. In case you dont know, when beta is higher than 1 then risk is higher and if beta is lower than 1, then risk will be low.

Now entering into the performance part of the article on CRISPR Therapeutics AG stock we should check the stocks actual performance in the past.

Performance of the CRSP Stock:

CRISPR Therapeutics AG revealed performance of -4.79% during the period of last 5 trading days and shown last 12 months performance of 9.76%. The stock moved to 6.38% in last six months and it maintained for the month at -17.09%. The stock noted year to date 2020 performance at -30.76% and changed about -29.66% over the last three months. The stock is now standing at -43.01% from 52 week-high and is situated at 30.56% above from 52-week low price.

Technical Indicators of CRISPR Therapeutics AG Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of CRISPR Therapeutics AG stock is 47.61.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for CRSP a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of CRSP is currently higher 4.18% from its 20 days moving average and trading -13.09% down the 50 days moving average. The stock price has been seen performing along below drift from its 200 days moving average with -17.19%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

CRISPR Therapeutics AG:

Operating Margin which tells about what proportion of a companys revenue is left over after paying for variable costs of production such as wages & raw materials is noted at 16.10%. Net profit margin of the company is 23.10% that shows how much the company is actually earning by every dollar of sales.

Return on Investment (ROI) of stock is 4.90%. ROI ratio tells about the efficiency of a number of investments in a company. Return on Assets (ROA) which shows how much the company is profitable as compared to its total assets is observed at 9.60%. Return on Equity (ROE), which tells about the profitability of the corporation by evaluating the profit it generates in ratio to the money shareholders have invested, is noted at 11.70%.

The price-to-earnings ratio or P/E is one of the most widely-used stock analysis tools to determine a stocks valuation that also shows whether a companys stock price is overvalued/overbought or undervalued/oversold. If P/E is lower, then stock can be considered undervalued and if its higher then the stock is overvalued. Price to earnings P/E of the stock is 43.43.

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $74.25.

Excerpt from:
CRISPR Therapeutics AG (CRSP) Stock, What You Won't Miss? - News Welcome

The genetic code to alllife on Earth, both simple and complex, comes down to four basic letters: A, C,T and G.

Untangling the role thatthese letters play in lifes blueprint has allowed scientists to understandwhat makes everything from bacteria to people the way they are. But as researchershave learned more, they have also sought ways to tinker with this blueprint,bringing ethical dilemmas into the spotlight. The Gene, a two-part PBS documentary from executive producer Ken Burnsairing April 7 and 14, explores the benefits and risks that come withdeciphering lifes code.

The film begins with oneof those ethical challenges. The opening moments describe how biophysicist HeJiankui used the gene-editing tool CRISPR/Cas9 to alter the embryos of twin girls who were born in China in 2018 (SN: 12/17/18). Worldwide, criticscondemned the move, claiming it was irresponsible to change the girls DNA, asexperts dont yet fully understand the consequences.

This moment heraldedthe arrival of a new era, narrator David Costabile says. An era in whichhumans are no longer at the mercy of their genes, but can control and evenchange them.

Headlines and summaries of the latest Science News articles, delivered to your inbox

The story sets the stagefor a prominent theme throughout the documentary: While genetics holdsincredible potential to improve the lives of people with genetic diseases,there are always those who will push science to its ethical limits. But thedriving force in the film is the inquisitive nature of the scientistsdetermined to uncover what makes us human.

The Gene, based on the book of the same name by Siddhartha Mukherjee (SN:12/18/16), one of the documentarys executive producers, highlights many ofthe most famous discoveries in genetics. The film chronicles Gregor Mendels classicpea experiments describing inheritance and how experts ultimately revealed inthe 1940s that DNA a so-called stupid molecule composed of just four chemicalbases, adenine (A), thymine (T),cytosine (C) and guanine (G) is responsible for storing geneticinformation. Historical footage, inBurns typical style, brings to life stories describing the discovery of DNAshelical structure in the 1950s and the success of the Human Genome Project indecoding the human genetic blueprint in 2003.

The film also touches ona few of the ethical violations that came from these discoveries. The eugenicsmovement in both Nazi Germany and the United States in the early 20th century aswell as the story of the first person to die in a clinical trial for genetherapy, in 1999, cast a morbid shadow on the narrative.

Interwoven into thistimeline are personal stories from people who suffer from genetic diseases.These vignettes help viewers grasp the hope new advances can give patients asexperts continue to wrangle with DNA in efforts to make those cures.

In the documentarysfirst installment, which focuses on the early days of genetics, viewers meet a family whose daughter is grappling with arare genetic mutation that causes her nerve cells to die. The family searchesfor a cure alongside geneticist Wendy Chung of Columbia University. The secondpart follows efforts to master the human genome and focuses on AudreyWinkelsas, a molecular biologist at the National Institutes of Health studyingspinal muscular atrophy, a disease she herself has, and a family fighting tosave their son from a severe form of the condition.

For science-interested viewers, the documentary does not disappoint. The Gene covers what seems to be every angle of genetics history from the ancient belief that sperm absorbed mystical vapors to pass traits down to offspring to the discovery of DNAs structure to modern gene editing. But the stories of the scientists and patients invested in overcoming diseases like Huntingtons and cancer make the film all the more captivating.

Follow this link:
The PBS documentary The Gene showcases genetics promise and pitfalls - Science News

New Jersey, United States: Market Research Intellect has added a new research report titled, Crispr And Crispr Associated Genes Market Professional Survey Report 2020 to its vast collection of research reports. The Crispr And Crispr Associated Genes market is expected to grow positively for the next five years 2020-2026.

The Crispr And Crispr Associated Genes market report studies past factors that helped the market to grow as well as, the ones hampering the market potential. This report also presents facts on historical data from 2011 to 2019 and forecasts until 2026, which makes it a valuable source of information for all the individuals and industries around the world. This report gives relevant market information in readily accessible documents with clearly presented graphs and statistics. This report also includes views of various industry executives, analysts, consultants, and marketing, sales, and product managers.

Key Players Mentioned in the Crispr And Crispr Associated Genes Market Research Report:

Market Segment as follows:

The global Crispr And Crispr Associated Genes Market report highly focuses on key industry players to identify the potential growth opportunities, along with the increased marketing activities is projected to accelerate market growth throughout the forecast period. Additionally, the market is expected to grow immensely throughout the forecast period owing to some primary factors fuelling the growth of this global market. Finally, the report provides detailed profile and data information analysis of leading Crispr And Crispr Associated Genes company.

Crispr And Crispr Associated Genes Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Crispr And Crispr Associated Genes market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Crispr And Crispr Associated Genes .

The Crispr And Crispr Associated Genes Market research presents a study by combining primary as well as secondary research. The report gives insights on the key factors concerned with generating and limiting Crispr And Crispr Associated Genes market growth. Additionally, the report also studies competitive developments, such as mergers and acquisitions, new partnerships, new contracts, and new product developments in the global Crispr And Crispr Associated Genes market. The past trends and future prospects included in this report makes it highly comprehensible for the analysis of the market. Moreover, The latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Crispr And Crispr Associated Genes market have also been included in the study.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.marketresearchintellect.com/ask-for-discount/?rid=202013&utm_source=SI&utm_medium=888

Table of Content

1 Introduction of Crispr And Crispr Associated Genes Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Crispr And Crispr Associated Genes Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Crispr And Crispr Associated Genes Market, By Deployment Model5.1 Overview

6 Crispr And Crispr Associated Genes Market, By Solution6.1 Overview

7 Crispr And Crispr Associated Genes Market, By Vertical7.1 Overview

8 Crispr And Crispr Associated Genes Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Crispr And Crispr Associated Genes Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.marketresearchintellect.com/product/crispr-and-crispr-associated-genes-market-size-and-forecast/?utm_source=SI&utm_medium=888

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Crispr And Crispr Associated Genes Market Size, Crispr And Crispr Associated Genes Market Growth, Crispr And Crispr Associated Genes Market Forecast, Crispr And Crispr Associated Genes Market Analysis, Crispr And Crispr Associated Genes Market Trends, Crispr And Crispr Associated Genes Market

Here is the original post:
Crispr And Crispr Associated Genes Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 - Science In Me

In recent years, the development of CRISPR technologies and gene-editing scissors in particular have taken the world by storm. Indeed, scientists have learned how to harness these clever natural systems in the biotech and pharmaceutical industries, among other areas.

New research from the University of Copenhagen shows that we are not the first to find a way to exploit the benefits of the CRISPR technique. Apparently, primitive bacterial parasites have been doing so for millions of years.

The researchers studied the least described and most enigmatic of the six CRISPR-Cas systems found in nature - Type IV CRISPR-Cas. Here, they uncovered characteristics that differ entirely from those in other systems.

Redefining CRISPR"Until recently, CRISPR-Cas was believed to be a defense system used by bacteria to protect themselves against invading parasites such as viruses, much like our very own immune system protects us. However, it appears that CRISPR is a tool that can be used for different purposes by diverse biological entities," according to 28-year-old Rafael Pinilla-Redondo, a PhD at UCPH's Department of Biology who led the research.

One of these biological entities are plasmids - small DNA molecules that often behave like parasites and, like viruses, require a host bacterium to survive.

"Here we found evidence that certain plasmids use type IV CRISPR-Cas systems to fight other plasmids competing over the same bacterial host. This is remarkable because, in doing so, plasmids have managed to turn the system around. Instead of protecting bacteria from their parasites, CRISPR is exploited to perform another task," says Pinilla-Redondo, adding:

"This is similar to how some birds compete for the best nesting site in a tree, or how hermit crabs fight for ownership of a shell."

"A humbling realization"The discovery challenges the notion that CRISPR-Cas systems have only one purpose in nature, that is, acting as immune systems in bacteria. According to Rafael Pinilla-Redondo, the discovery gives some additional perspective:

"We humans have only recently begun to exploit nature's CRISPR-Cas systems, but as it turns out, we are not the first. These 'primitive parasites' have been using them for millions of years, long before humans. It is quite a humbling realization"

What can we use it for?The researchers speculate that these systems could be used to combat one of the greatest threats to humanity: multi-drug resistant bacteria. Hundreds of thousands of people die from MDR bacteria every year.

Bacteria become resistant to antibiotics by acquiring genes that make them resistant to antibiotic treatment. Very frequently, this occurs when plasmids transport antibiotic resistant genes from one bacterium to another.

"As this system appears to have evolved to specifically attack plasmids, it is plausible that we could repurpose it to fight plasmids carrying antibiotic resistant genes. This could be achieved because it is possible to program CRISPR to target what one wants" says Pinilla-Redondo.

Research paper

Related LinksUniversity Of CopenhagenLands Beyond Beyond - extra solar planets - news and scienceLife Beyond Earth

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.

Read this article:
Humans are not the first to repurpose CRISPR - Space Daily

What happened

March wasn't kind to any asset class because of the COVID-19 pandemic. But the month took a particularly heavy toll on risky clinical-stage biotech stocks. Shares ofAdaptimmune Therapeutics(NASDAQ:ADAP), Atreca (NASDAQ:BCEL), and CRISPR Therapeutics(NASDAQ:CRSP), for instance, each fell by more than 20% last month,according to data fromS&P Global Market Intelligence.

Why did clinical-stage biotech stocks tank last month? Companies like Adaptimmune, Atreca, and even CRISPR are heavily dependent on secondary stock offerings to raise capital for their costly clinical activities. What's more, these types of companies are essentially a science experiment, which entails a whole lot of risk.

Image source: Getty Images.

So with the market in meltdown mode over the COVID-19 pandemic, investors clearly lost their appetite for risk in general, especially among companies that have to dilute shareholders on a regular basis to generate operating capital. The good news is that Adaptimmune, Atreca, and CRISPR are all now trading at extremely attractive valuations after last month's bloodbath.

Adaptimmune is an anti-cancer cell therapy company that sports multiple high-end partnerships. Moreover, the company is less than two years away from potentially bringing its first product to market --an experimentalsynovial sarcoma treatment known asADP-A2M4. With Adaptimmune's market cap falling to a mere $342 million after last month's emotionally charged sell-off, its stock comes across as dirt cheap right now. The company, after all, is targeting several high-value indications in a market -- oncology -- that's one of the fastest growing in all of heatlhcare.

Atreca, for its part, is a developmental biotech focused ontherapies derived from the immune responses of cancer patients. The company sports several A-list investors such as the Baker Bros. and theBill and Melinda Gates Foundation. The main downside with this company is that it lacks a late-stage product candidate, meaning it will probably remain a cash-burning clinical-stage company for several more years.

That said, its novel immunotherapy platform might also attract a deep-pocketed partner or perhaps a tender offer in the not-so-distant future. As such, Atreca might also be a worthwhile pickup for risk-tolerant biotech investors on this hefty pullback.

CRISPR is a pioneer in the relatively young field ofCRISPR/Cas9 gene editing. The company is currently evaluating its first product candidate, CTX001, in a pair of early stage trials for the rare blood disorders sickle cell disease and transfusion-dependent beta thalassemia. If these ongoing trials support further development for CTX001, CRISPR could very well end up fetching a noteworthy buyout offer.

So while CRISPR is a risky biotech stock to be sure, it does offer a healthy upside potential for aggressive investors. Stated simply, CRISPR's March swoon may be an outstanding buying opportunity for the risk-tolerant crowd.

Follow this link:
Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March - Motley Fool

The drug giant GlaxoSmithKline said Monday it will collaborate with Vir Biotechnology on experimental treatments and potentially, vaccines against the novel coronavirus.

As part of the deal, GlaxoSmithKline will invest $250 million in the San Francisco startup at a 10% premium to the companys closing share price on March 27.

The agreement includes Virs lead drugs against the novel coronavirus, which are monoclonal antibodies that could enter efficacy studies in humans in three to five months. The deal includes an early effort to use CRISPR, the gene-editing technology, to identify medicines that might help the immune system fight off viruses. The collaboration also encompasses a long-term project to develop a vaccine that might prevent infection not only with the virus, called SARS-CoV-2, but related viruses that could cause problems in the future.

advertisement

Virs unique antibody platform has precedented success in identifying and developing antibodies as treatments for multiple pathogens, Hal Barron, GlaxoSmithKlines chief scientific officer, said in a statement.

George Scangos, Virs chief executive officer, said the antibodies were isolated from a patient who previously had severe acute respiratory syndrome, or SARS, a disease caused by another coronavirus that sickened thousands in 2003 and 2004.

advertisement

Antibodies that are isolated, lets say years after an infection often have properties that you dont find in antibodies isolated immediately after, Scangos said. When SARS-CoV-2 started spreading, Sangos said the company had a running start because we already had those SARS antibodies.

Virs drugs in development are both based on a single antibody from this patient, and both have been modified so that they will last longer in the body. The company has altered one of the drugs in a bid to create long-term immunity, much like a vaccine. That particular technology has never been tested in humans before.

Antibody drugs could be used in three possible ways: to prevent people at high risk, such as healthcare workers, from ever becoming infected; to prevent those infected from developing severe respiratory problems that can make Covid-19, the disease caused by the virus, deadly; and to treat people who are already in respiratory distress. Vir expects to start trials for all three uses this summer.

Other companies are working on similar treatments, including Regeneron Pharmaceuticals, which has said it will begin testing cocktails of its antibody drugs this summer. Abcellera and Eli Lilly have said they could start tests of antibody drugs around the same time. Brii Biosciences is also developing antibody drugs against the virus, as is a team from pharmaceutical giant Amgen and Adaptive Biosciences.

Vir and GlaxoSmithKlines collaboration will also lead to longer-term research, including projects using CRISPR, which both companies are already using in their work. The tool based on enzymes that bacteria use to defend themselves against viruses can be used to edit the genes in human cells in culture. Scientists can then see whether genetic changes render the cells more resistant to viruses. In a few cases, Scangos said, that approach has helped identify existing experimental drug molecules that might help the immune system fight off viruses.

The two companies will also work together to test whether Virs antibodies can be used to identify the weak spots of the virus, which might also be shared by other coronaviruses. If thats the case, Scangos said it could help researchers develop vaccines that can target not only SARS-CoV-2, but future viral threats. That work, however, is at a very early stage.

Correction: a previous version of this story misstated the stock premium GSK paid.

View post:
GlaxoSmithKline and Vir collaborate to take on Covid-19 - STAT

CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology bothin vivoandex vivo,announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application submitted by its collaborator, Novartis, for a CRISPR/Cas9-based engineered cell therapy for the treatment of sickle cell disease (SCD).

This Phase 1/2 clinical trial will begin investigating OTQ923 in adult patients with severe complications of SCD. OTQ923 is a SCD treatment based on genome editing of hematopoietic stem cells (HSCs), using CRISPR/Cas9 RNA guides identified through Intellias cell therapy research collaboration with Novartis. This therapeutic approach results in highly targeted editing of the HSCs DNA to induce fetal hemoglobin (HbF) expression. The edited cells are returned to the patient, where the expression of HbF is expected to reduce the deleterious effects of sickle hemoglobin (HbS). Novartis IND application triggered a milestone payment to Intellia, and the company is eligible to receive additional downstream success-based milestones and royalties.

We are pleased to have worked alongside our colleagues at Novartis to achieve this important milestone, which moves this CRISPR/Cas9-based engineered cell therapy into the clinic, with the potential to significantly impact the lives of patients who suffer from sickle cell disease, said Intellia Chief Operating Officer and Executive Vice President Andrew Schiermeier, Ph.D. Our research with Novartis over the past five years has laid the groundwork for the development of next-generation CRISPR/Cas9-based cell therapies for patients. Intellia looks forward to Novartis efforts to advance other targets that were selected to develop as additional CRISPR/Cas9-based cell therapy products.

About Intellias Engineered Cell Therapy Programs

From December 2014 through December 2019, Intellia and Novartis jointly researched CRISPR/Cas9-based cell therapies in various cell types, including certain stem cells and T cells. In parallel with its ex vivo collaboration with Novartis, Intellia has been advancing its wholly owned ex vivo pipeline of immuno-oncology and autoimmune cell therapies. Intellias proprietary ex vivo programs include its acute myeloid leukemia (AML) program utilizing transgenic T cell receptors (TCRs) against Wilms Tumor 1 (WT1), a target identified in collaboration with IRCCS Ospedale San Raffaele (OSR). Intellia plans to submit an IND application for NTLA-5001, the companys development candidate for the treatment of AML, in the first half of 2021. View Intellias programs pipeline for more information.

About Intellia Therapeutics

Intellia Therapeuticsis a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more aboutIntellia Therapeuticsand CRISPR/Cas9 atintelliatx.comand follow us on Twitter @intelliatweets.

Forward-Looking Statements

This press release contains forward-looking statements of Intellia Therapeutics, Inc. (Intellia or the Company) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellias beliefs and expectations regarding its: planned submission of an investigational new drug (IND) application or similar clinical trial application for NTLA-5001, its first T cell receptor (TCR)-directed engineered cell therapy development candidate for its acute myeloid leukemia (AML) program in the first half of 2021; plans to advance and complete preclinical studies for its other in vivo and ex vivo programs; advancement and expansion of its CRISPR/Cas9 technology to develop human therapeutic products, as well as its ability to maintain and expand its related intellectual property portfolio; ability to demonstrate its platforms modularity and replicate or apply results achieved in preclinical studies in any future studies, including human clinical trials; ability to develop other in vivo or ex vivo cell therapeutics of all types, and those targeting WT1 in AML in particular, using CRISPR/Cas9 technology; ability to optimize the impact of its collaborations on its development programs, including but not limited to its collaborations with Novartis and OSR; statements regarding the timing of regulatory filings regarding its development programs; use of capital, expenses, future accumulated deficit and other 2019 financial results or in the future; and ability to fund operations through the end of 2021.

Story continues

Any forward-looking statements in this press release are based on managements current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellias ability to protect and maintain its intellectual property position; risks related to Intellias relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Intellias product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the risk that Intellias collaborations with Novartis or its other ex vivo collaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellias actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in Intellias most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellias other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Intellia Contacts:

Media:Jennifer Mound SmoterSenior Vice President External Affairs & Communications +1 857-706-1071 jenn.smoter@intelliatx.com

Lynnea OlivarezDirectorExternal Affairs & Communications+1 956-330-1917lynnea.olivarez@intelliatx.com

Investors:Lina LiAssociate DirectorInvestor Relations+1 857-706-1612lina.li@intelliatx.com

Originally posted here:
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with...

But things get even trickier when one talks about editing the DNA in sperm or egg cells, which would then affect multiple generations to come. Expert Fyodor Urnov says in the film hes dead set against such genetic modifications. We might think its okay or even admirable to edit the genome of a terminally ill cancer patient so they did not feel pain, he notes. But what about editing that same gene to create a generation of invulnerable super soldiers? Everyone seems to draw the line between acceptable and unacceptable in a different place, and Human Nature is refreshingly open to all voices in the debate.

Human Nature is divided up into chapters, walking the audience through the science and its implications through interviews with researchers, journalists and ethicists. Bolt often interviews them sitting at their dining room tables, talking passionately about their work as if they were excitedly chatting with a friend.

A couple of the interviewees are connected with the University of Wisconsin-Madison, one of the leaders in gene therapy. Rodolphe Barrangou is a former Ph.D. student at the UW, and you might have seen him tooling around Madison in his car with CRISPR license plates.

Also appearing in the film is UW bioethicist and Star Trek fan Alta Charo, who takes an even-handed approach to the debate, noting that the technology is merely a tool, neither inherently good or evil. What you do with the power determines if the result is something we applaud or something we deplore, she said. But its not the tool that determines the endpoint. Its the user.

Read the original:
Movie review: 'Human Nature' is a crisp and engaging look at DNA therapy - Madison.com

Global CRISPR and Cas Genes market size will reach xx million US$ by 2025, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019-2025 as the forecast period to estimate the market size for CRISPR and Cas Genes .

This industry study presents the global CRISPR and Cas Genes market size, historical breakdown data (2014-2019) and forecast (2019-2025). The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of CRISPR and Cas Genes market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

Request Sample Report @https://www.mrrse.com/sample/17251?source=atm

Global CRISPR and Cas Genes market report coverage:

The CRISPR and Cas Genes market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The CRISPR and Cas Genes market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The following manufacturers are covered in this CRISPR and Cas Genes market report:

Companies Mentioned in the Report

The report also profiles the major players in the market in terms of various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players operating in the global CRISPR and Cas genes market include Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell Inc. These players are adopting organic and in-organic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and market share.

The global CRISPR and Cas genes market has been segmented as follows:

Global CRISPR and Cas Genes Market, by Product

Global CRISPR and Cas Genes Market, by Application

Global CRISPR and Cas Genes Market, by End-user

Global CRISPR and Cas Genes Market, by Region

Buy This Report @ https://www.mrrse.com/checkout/17251?source=atm

The study objectives are CRISPR and Cas Genes Market Report:

In this study, the years considered to estimate the market size of CRISPR and Cas Genes Market:

History Year: 2014 2018

Base Year: 2018

Estimated Year: 2019

Forecast Year: 2019 2025

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/17251?source=atm

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of CRISPR and Cas Genes market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Link:
CRISPR and Cas Genes Market Information, Figures and Analytical Insights 2019 2025 - Daily Science

It was supposed to be an exciting time of next-gen science, where CRISPR gene editing was being used in the first series of human trials in the hope this tech could help cure a range of diseases.

But one of its proponents, CRISPR Therapeutics, has, alongside a growing number of biopharmas, admitted the spreading COVID-19 pandemic is starting to see it be adversely affected.

In a Securities and Exchange Commission filing Tuesday, the biotech said: We are conducting a number of clinical trials for product candidates in the fields of severe hemoglobinopathies and immuno-oncology in geographies which are affected by the coronavirus pandemic.

We believe that the coronavirus pandemic has had, and will likely continue to have, an impact on various aspects of our clinical trials. For example, with respect to our CTX001 clinical trials for severe hemoglobinopathies (specifically, transfusion-dependent beta thalassemia and severe sickle cell disease), since[intensive care unit] beds and related healthcare resources are anticipated to become significantly constrained in light of the coronavirus pandemic, no additional patients are currently scheduled to begin dosing in either study at this time.

CTX001 is an investigational CRISPR gene-edited therapy for patients suffering from beta thalassemia and sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. This is currently in a long-term follow-up trial after posting some encouraging, though early, results in several patients late last year.

Looking at its cancer trials, it also added that investigators will likely not want to expose cancer patients to COVID-19 since the dosing of patients is conducted within an in-patient setting, which could also hit it tests.

RELATED: Pandemic sees one-quarter of investigators halting trial enrollment: poll

Its leading immuno-oncology cell therapy programs, CTX110 and CTX120, are using an allogenic approach to tumor targets. CTX110 targets CD19, an antigen expressed in various B-cell malignancies, while CTX120 targets BCMA, an antigen expressed in multiple myeloma.

Its third candidate, CTX130, is focused on solid tumorsand targets CD70, an antigen expressed on both hematologic cancers, including certain lymphomas, as well as solid tumors including renal cell carcinoma.

CTX110 started an early safety trial last summer, and the biotech said in its financial report back in February that it was still enrolling patients to assess the safety and efficacy of CTX120. Meanwhile, CTX130 is yet to enter the clinic.

The biotech has already closed its offices and asked that most of its staffers work remotely. It said it has restricted on-site staff to only those personnel and contractors who must perform essential activities that must be completed on-site and limited the number of staff in any given research and development laboratory.

But this comes with its own issues: Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors.

It also said that, given that its labs are not easily accessible and talking to regulators is getting tough, there could be a delay for the timely completion of preclinical activities, including IND-enabling studies as well as its ability to select future development candidates and initiation of additional clinical trials for otherdevelopment programs.

Finances for the biotech may be hit, too.The trading prices for our common shares and other biopharmaceutical companies have been highly volatile as a result of the coronavirus pandemic, the company said. As a result, we may face difficulties raising capital through sales of our common shares or such sales may be on unfavorable terms.

The biotech has seen its shares yo-yo over the past month as COVID-19 ramped updown from more than $53 a share at the start of Marchto less than $43 just two weeks laterand ended the month at around $42.

In short, CRISPR is braced for the worst but does not know how deeply this could cut into its trial and business. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely.

Read more:
CRISPR Therapeutics braces for 'severe impact' from COVID-19 crisis - FierceBiotech

CRISPR-Cas9, which is short for clustered, regularly interspaced short palindromic repeats and CRISPR-associated protein 9. The technique is faster, cheaper, more accurate, and more efficient than other existing genome editing methods.

For the CRISPR-Cas9 system to work, a bacterial defense protein got Cas9 seeks out an adjacent protospacer motif (PAM) that is present in the viral DNA yet not in the bacterial DNA. CRISPR-Cas9 has been harnessed for editing the human genome because such PAM sequences are also quite common in our DNA; however, genes that are not near a PAM cannot be targeted.

To conquer this problem, a team led by Benjamin P. Kleinstiver, a biochemist at MGHs Center for Genomic Medicine, engineered variations of a Cas9 protein that dont require a particular PAM to bind and cut DNA. The two new Cas9 variations, named SpG and SpRY, allow editing of DNA sequences at efficiencies not achievable with conventional CRISPR-Cas9 enzymes.

As engineered proteins target independently, they enable targeting of previously inaccessible regions of the genome.

Benjamin P. Kleinstiver, a biochemist at MGHs Center for Genomic Medicine, said,By nearly completely relaxing the requirement for the enzymes to recognize a PAM, many genome editing applications are now possible. And since almost the entire genome is targetable, one of the most exciting implications is that that the entire genome is druggable from a DNA-editing perspective.

Scientists are further planning to comprehend the function of these proteins. They also want to explore their unique capabilities for a variety of different applications.

Lead author Russell T. Walton, also of MGHs Center for Genomic Medicine, said,We have demonstrated that these new enzymes will allow researchers to generate biologically and clinically relevant genetic modifications that were previously unfeasible.

Read more here:
Scientists expanded the Capabilities of CRISPR gene editing technique - Tech Explorist

TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Modalis) today announced that the company has entered into a license agreement with Editas Medicine, Inc., under which Modalis has obtained a license to certain intellectual property that is controlled by Editas Medicine. Modalis is utilizing its proprietary epigenetic gene modulation technology, CRISPR-GNDM (Guide Nucleotide Directed Modulation), to treat patients with serious genetic disorders. Additional details including financial terms of the agreement were not disclosed.

"Our goal is to create CRISPR based gene therapies for genetic disorders, most of which fall into the orphan disease category. There should be no disease that is ignored because of its small patient population, and our mission to develop disease modifying treatments for these diseases reflects our belief that Every Life Deserves Attention. We are proud to be the pioneer in CRISPR based gene modulation therapy, said Haru Morita, Chief Executive Officer of Modalis.

We are pleased to establish this license agreement with Modalis Therapeutics as their mission is aligned with our mission to make transformative medicines for people living with serious diseases of unmet clinical need. CRISPR technology has many uses and applications, and we are pleased to include Modalis in our expanding portfolio of licensees so the greatest number of patients may benefit in the future from transformative medicines, said Cynthia Collins, president and chief executive officer, Editas Medicine.

About Modalis

Modalis Therapeutics is developing precision genetic medicines through epigenetic gene modulation. Founded by Osamu Nureki and leading scientists in CRISPR gene editing from University of Tokyo, Modalis is pursuing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double-stranded DNA cleavage, gene editing or base editing. Modalis is focusing initially on genetic disorders caused by loss of gene regulation resulting in excess or insufficient protein production which includes more than 660 genes that are currently estimated to cause human disease due to haploinsufficiency. Headquartered in Tokyo with laboratories and facilities in Cambridge, Massachusetts, the company is backed by leading Japanese investors including Fast Track Initiative, SBI Investment, UTokyo-IPC, SMBC Venture Capital, and Mizuho Capital. For additional information, visit http://www.modalistx.com.

Original post:
Modalis Obtains Access to Foundational CRISPR IP - Business Wire

Documentary "Human Nature" examines how gene editing can help - and hurt - humanity.

If youre familiar with the Replicates from Blade Runner, the velociraptors from Jurassic Park or the genetic engineering so chillingly laid out in Aldous Huxleys novel Brave New World, youll be fascinated by how much science fiction has become science fact in Adam Bolts Human Nature. And its all due to CRISPR (pronounced crisper), a gene-altering technology that not only could facilitate designer babies, but possibly play a central role in putting the clamps on another acronym, COVID-19.

That timeliness is obviously on the side of Human Nature, a snazzy-looking documentary using sparkling graphics and top geneticists, journalists and one very adorable sickle-cell anemic to spell out a complicated subject in compelling, easy-to-grasp terms. But that same timeliness also works against it, given how now is not an advantageous moment for the films commercial aspects amid a landscape of shuttered theaters and a frightened populace whod like to avoid anything to do with medicine and science as sources of entertainment.

Yet, that double-edged sword fits snuggly in the wheelhouse of CRISPR (short for clustered regularly interspaced short palindromic repeats), a microorganism able to locate and repair defective DNA, as well as fend off invading viruses like COVID-19 by acting as a defense shield mimicking the offenders own DNA. But like the Internet, a revolutionary breakthrough for which CRISPR is often compared, theres a serious downside involving the morality of whether humans should have the right to, as the film calls it, play God. Namely, should parents be allowed to treat an embryo the same way theyd approach ordering a pizza? Well have the regular with blue eyes, blonde hair and an IQ of Einstein. Oh, and could you throw in some immense athletic ability, too?

Clearly, CRISPR has the potential to put us at the mercy of the type of mad scientists weve become accustomed to in just about every Bond film ever made. One geneticist, whose very name, Jennifer Doudna, includes DNA, admits having had a nightmare in which she comes face-to-face with Adolf Hitler! Are we willing to toy with the very real prospect of creating a master race?

Thats just one of the troubling questions Bolt confronts you with while weighing the pros and cons of a new frontier brimming in possibilities and danger. Personally, I come down on the side of CRISPRs benefits, particularly after meeting David Sanchez, a teen with sickle cell thats spent about half of his young life in hospitals receiving precious blood transfusions. Hes smart, personable and amazingly brave, so much so, you cant help but be all in when CRISPR offers him a chance at a more normal life. Yet, hes just as quick to recall to how hes learned to embrace -- even appreciate -- his illness because its made him a better, more resourceful kid, insights he would not have acquired had CRISPR been available when he was in utero. See? Hes torn, too.

Do we embrace a discovery wielding the promise of curing and preventing cancers and birth defects, or shun it for its ability to rob us of our unique individuality? Its a compelling argument I frankly wish Bolt had expanded more upon in his movies all-too-brief 90 minutes. But whats here is more than enough to spark a multitude of kitchen-table conversations about where we should set the limits on science, and more importantly, who should be making those decisions.

Given the disarray COVID-19 has put the world in, now probably isnt the time for us to evaluate, especially when CRISPR could well determine our fate by ridding our planet of a crippling plague. But what about after? Will, as Trump is fond to say, the cure be worse than the disease? Its a question for which Human Nature holds no answers, only utopian and despotic possibilities well be forced to uneasily choose between when and if the time comes.

See the original post:
Movie review: Doc Human Nature strikes a nerve in the age of coronavirus - The Patriot Ledger

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy long-term Treasury bonds. Our article also called for a total international travel ban. While we were warning you, President Trump minimized the threat and failed to act promptly. As a result of his inaction, we will now experience a deeper recession (see why hell is coming).

In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 835 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of December 31st, 2019. In this article we are going to take a look at smart money sentiment towards CRISPR Therapeutics AG (NASDAQ:CRSP).

Is CRISPR Therapeutics AG (NASDAQ:CRSP) the right investment to pursue these days? The best stock pickers are becoming hopeful. The number of long hedge fund bets improved by 13 recently. Our calculations also showed that CRSP isn't among the 30 most popular stocks among hedge funds (click for Q4 rankings and see the video at the end of this article for Q3 rankings).

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey's monthly stock picks returned 72.9% since March 2017 and outperformed the S&P 500 ETFs by more than 41 percentage points. Our short strategy outperformed the S&P 500 short ETFs by 20 percentage points annually (see the details here). That's why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.

Samuel Isaly Orbimed Advisors

We leave no stone unturned when looking for the next great investment idea. For example we recently identified a stock that trades 25% below the net cash on its balance sheet. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences, and go through short-term trade recommendations likethis one. We even check out the recommendations of services with hard to believe track records. Our best call in 2020 was shorting the market when S&P 500 was trading at 3150 after realizing the coronavirus pandemic's significance before most investors. Now let's take a gander at the new hedge fund action encompassing CRISPR Therapeutics AG (NASDAQ:CRSP).

At Q4's end, a total of 30 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 76% from the third quarter of 2019. By comparison, 11 hedge funds held shares or bullish call options in CRSP a year ago. With hedgies' capital changing hands, there exists an "upper tier" of noteworthy hedge fund managers who were upping their stakes significantly (or already accumulated large positions).

Is CRSP A Good Stock To Buy?

Story continues

Of the funds tracked by Insider Monkey, Cormorant Asset Management, managed by Bihua Chen, holds the number one position in CRISPR Therapeutics AG (NASDAQ:CRSP). Cormorant Asset Management has a $60.9 million position in the stock, comprising 2.4% of its 13F portfolio. Coming in second is OrbiMed Advisors, managed by Samuel Isaly, which holds a $46.7 million position; the fund has 0.7% of its 13F portfolio invested in the stock. Some other hedge funds and institutional investors that hold long positions contain Charles Clough's Clough Capital Partners, Renaissance Technologies and Farallon Capital. In terms of the portfolio weights assigned to each position Cormorant Asset Management allocated the biggest weight to CRISPR Therapeutics AG (NASDAQ:CRSP), around 2.43% of its 13F portfolio. Clough Capital Partners is also relatively very bullish on the stock, earmarking 2.31 percent of its 13F equity portfolio to CRSP.

As aggregate interest increased, some big names have jumped into CRISPR Therapeutics AG (NASDAQ:CRSP) headfirst. Citadel Investment Group, managed by Ken Griffin, established the largest position in CRISPR Therapeutics AG (NASDAQ:CRSP). Citadel Investment Group had $12.6 million invested in the company at the end of the quarter. Peter Rathjens, Bruce Clarke and John Campbell's Arrowstreet Capital also initiated a $6.3 million position during the quarter. The other funds with new positions in the stock are Benjamin A. Smith's Laurion Capital Management, Principal Global Investors's Columbus Circle Investors, and David Harding's Winton Capital Management.

Let's check out hedge fund activity in other stocks - not necessarily in the same industry as CRISPR Therapeutics AG (NASDAQ:CRSP) but similarly valued. These stocks are Lithia Motors Inc (NYSE:LAD), Cimpress NV (NASDAQ:CMPR), Equitrans Midstream Corporation (NYSE:ETRN), and Graham Holdings Co (NYSE:GHC). This group of stocks' market values are similar to CRSP's market value.

[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position LAD,29,661944,3 CMPR,18,707978,6 ETRN,15,379764,-2 GHC,18,510146,0 Average,20,564958,1.75 [/table]

View table hereif you experience formatting issues.

As you can see these stocks had an average of 20 hedge funds with bullish positions and the average amount invested in these stocks was $565 million. That figure was $298 million in CRSP's case. Lithia Motors Inc (NYSE:LAD) is the most popular stock in this table. On the other hand Equitrans Midstream Corporation (NYSE:ETRN) is the least popular one with only 15 bullish hedge fund positions. Compared to these stocks CRISPR Therapeutics AG (NASDAQ:CRSP) is more popular among hedge funds. Our calculations showed that top 20 most popular stocks among hedge funds returned 41.3% in 2019 and outperformed the S&P 500 ETF (SPY) by 10.1 percentage points. These stocks lost 17.4% in 2020 through March 25th and still beat the market by 5.5 percentage points. Unfortunately CRSP wasn't nearly as popular as these 20 stocks and hedge funds that were betting on CRSP were disappointed as the stock returned -31.4% during the first two and a half months of 2020 (through March 25th) and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as most of these stocks already outperformed the market in Q1. Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

5 Most Popular Stocks Among Hedge Funds

Disclosure: None. This article was originally published at Insider Monkey.

Related Content

Continue reading here:
Hedge Funds Have Never Been This Bullish On CRISPR Therapeutics AG (CRSP) - Yahoo Finance

Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Crispr Therapeutics AG (CRSP) yesterday and set a price target of $80.00. The companys shares closed last Tuesday at $42.41.

According to TipRanks.com, Tuerkcan is a 4-star analyst with an average return of 15.6% and a 37.5% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intellia Therapeutics, and Seattle Genetics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $71.68 average price target.

See todays analyst top recommended stocks >>

Crispr Therapeutics AGs market cap is currently $2.69B and has a P/E ratio of 42.70. The company has a Price to Book ratio of 2.71.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Continue reading here:
Oppenheimer Maintains Their Buy Rating on Crispr Therapeutics AG (CRSP) - Smarter Analyst

Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on Crispr Therapeutics AG (CRSP) today and set a price target of $80.00. The companys shares closed last Tuesday at $42.41.

According to TipRanks.com, Lee is a 3-star analyst with an average return of 0.1% and a 43.0% success rate. Lee covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Karyopharm Therapeutics.

Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $71.68, representing a 62.2% upside. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $80.00 price target.

See todays analyst top recommended stocks >>

Based on Crispr Therapeutics AGs latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $77.02 million and net profit of $30.54 million. In comparison, last year the company earned revenue of $115K and had a GAAP net loss of $47.59 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Read the rest here:
Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Canaccord Genuity - Smarter Analyst

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available this week, for the May 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new May 8th contracts and identified one put and one call contract of particular interest.

The put contract at the $41.00 strike price has a current bid of $3.30. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $41.00, but will also collect the premium, putting the cost basis of the shares at $37.70 (before broker commissions). To an investor already interested in purchasing shares of CRSP, that could represent an attractive alternative to paying $42.60/share today.

Because the $41.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 62%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 8.05% return on the cash commitment, or 75.33% annualized at Stock Options Channel we call this the YieldBoost.

Below is a chart showing the trailing twelve month trading history for CRISPR Therapeutics AG, and highlighting in green where the $41.00 strike is located relative to that history:

Turning to the calls side of the option chain, the call contract at the $43.00 strike price has a current bid of $3.30. If an investor was to purchase shares of CRSP stock at the current price level of $42.60/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $43.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.69% if the stock gets called away at the May 8th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if CRSP shares really soar, which is why looking at the trailing twelve month trading history for CRISPR Therapeutics AG, as well as studying the business fundamentals becomes important. Below is a chart showing CRSP's trailing twelve month trading history, with the $43.00 strike highlighted in red:

Considering the fact that the $43.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 48%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 7.75% boost of extra return to the investor, or 72.50% annualized, which we refer to as the YieldBoost.

The implied volatility in the put contract example is 141%, while the implied volatility in the call contract example is 135%.

Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $42.60) to be 61%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.

Top YieldBoost Calls of the S&P 500

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read this article:
First Week of May 8th Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq

As part of ongoing efforts to try to reduce the spread of COVID-19, researchers around the world are working hard to develop novel diagnostic technologies. Rapid and simple identification of people infected with SARS-CoV-2 plays a crucial role in reducing transmission of the virus, by enabling appropriate isolation measures and contact tracing to take place.The lab of Dr Changchun Liu at the University of Connecticut Health Center has recently reported progress in this area, with the development of a simple, low-cost, CRISPR-based method which can detect infectious diseases such as COVID-19.1 Technology Networks spoke to Dr Liu to learn more about the method, the advantages it offers over PCR-based methods of detection, and the next steps to be taken before a point-of-care diagnostic test using this method could become widely available.Anna MacDonald (AM): Many of the current diagnostic tests for infectious diseases such as COVID-19 are PCR-based. Why is this method currently the gold standard and what are some of the limitations associated with it?

Changchun Liu (CL): PCR/RT-PCR, particularly real-time PCR/RT-PCR, provides a highly sensitive and specific method for detection of infectious diseases (e.g., COVID-19). In addition, PCR/RT-PCR-based methods can enable early diagnosis of COVID-19 because it detects nucleic acid (e.g., RNA) of novel coronavirus SARS-CoV-2. PCR/RT-PCR-based methods are typically restricted in a centralized clinical laboratory due to the requirement for sophisticated equipment and well-trained personnel, which are not suitable for simple, rapid, point of care diagnostic applications. AM: What advantages could CRISPR-based detectionoffer? What is limiting greater use of these methods for the detection of infectious diseases so far? CL: CRISPR-based nucleic acid detection provides a highly sensitive, specific and reliable testing approach for nucleic acid-based molecular diagnostics. Unlike PCR-based methods, CRISPR-based nucleic acid detection methods can work at a constant temperature (e.g. 37oC) without the need for an expensive thermal cycler (e.g. PCR machine). However, currently available CRISPR-based nucleic acid detection methods typically require: i) separate nucleic acid amplification in different reaction systems, and ii) multiple manual operations, which undoubtedly complicates the testing procedures and potentially increases the risk of carry-over contaminations due to amplification products transferring.

AM: Can you tell us more about the CRISPR-based method you have developed and give us an overview of your studys results? CL: We developed an All-In-One Dual CRISPR-Cas12a (termed "AIOD-CRISPR") assay method for rapid, ultrasensitive, specific and visual detection of nucleic acid. To improve detection sensitivity, we have proposed a dual CRISPR-Cas12a detection strategy. In addition, unlike previous CRISPR-based nucleic acid detections, all reagents for nucleic acid detection in our AIOD-CRISPR assay can be incubated in one-pot, enabling simple, rapid, sensitive and specific nucleic acid detection. Our AIOD-CRISPR assay method has successfully been utilized to detect nucleic acids (DNA and RNA) of the SARS-CoV-2 and HIV with a sensitivity of a few copies. Also, it was evaluated by detecting HIV-1 RNA extracted from human plasma samples, achieving a comparable sensitivity with real-time RT-PCR, but within a shorter time (less than 20 minutes). AM: How does AIOD-CRISPR compare to other CRISPR-based detection methods?

CL: As mentioned above, we developed a dual CRISPR-Cas12a detection strategy to improve detection sensitivity in our AIOD-CRISPR assay. In addition, unlike previously reported CRISPR-based nucleic acid detections, all reagents of our AIOD-CRISPR assay can be incubated in one-pot, eliminating need for multiple manual operations and enabling simple, rapid point of care diagnostics. In summary, our AIOD-CRISPR assay provides a simple, rapid (typically 5-20 minutes), ultrasensitive (few copies) and highly specific method for nucleic acid-based molecular diagnostics at the point-of-care. AM: Why is a one-pot reaction system so important? CL: As mentioned above, previously reported CRISPR-based nucleic acid detections typically require separate nucleic acid amplification and multiple manual operations, which undoubtedly complicates the testing procedures and is not ideal for point of care diagnostics. In our AIOD-CRISPR assay, all components for isothermal amplification and CRISPR-based detection are prepared in a one-pot format, which greatly simplifies the detection procedures and eliminates the risk of carry-over contaminations. Thus, our AIOD-CRISPR assay method has a great potential for developing next-generation point-of-care molecular diagnostics. AM: What are the next steps before a point-of-care diagnostic test using this method could become widely available? CL: We are integrating our AIOD-CRISPR assay into our microfluidic diagnostic chip to develop a simple, rapid, affordable, point-of-care diagnostic platform for SARS-CoV-2 detection at home or small clinics. We have long focused on developing simple, low-cost, point-of-care diagnostic technologies for rapid detection of infectious diseases. For instance, during the 2015-2016 Zika outbreak, we developed an instrument-free point-of-care molecular diagnostic technology for Zika virus detection.2 AM: What difference could a rapid, affordable, point-of-care test such as the one you are developing make to the global response to the COVID-19 pandemic?

CL: Rapid and early detection of the SARS-CoV-2 virus plays a crucial role in facilitating early intervention and treatment (e.g. home isolation, social distancing) and preventing COVID-19 disease spread. We envision that such a simple, rapid, affordable, and point-of-care diagnostics technology can be widely used for detection of the SARS-CoV-2 at home or in small clinics, preventing or slowing the rapid spread of COVID-19. AM: Your method was used to detect SARs-CoV-2 and HIV could it be easily adapted in the future for other possible infectious disease outbreaks? CL: Yes, as a platform technology, our AIOD-CRISPR assay method can be easily adapted to detect other infectious disease in the future.

Changchun Liu, Associate Professor, Department of Biomedical Engineering, University of Connecticut Health Center, was speaking to Anna MacDonald, Science Writer, Technology Networks. References:

1: Ding, X., Yin, K., Li, Z., & Liu, C. (2020). All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus. https://doi.org/10.1101/2020.03.19.998724

2: Song, J., Mauk, M. G., Hackett, B. A., Cherry, S., Bau, H. H., & Liu, C. (2016). Instrument-Free Point-of-Care Molecular Detection of Zika Virus. Analytical Chemistry, 88(14), 72897294. https://doi.org/10.1021/acs.analchem.6b01632

Read more here:
A Point-of-Care CRISPR-based COVID-19 Diagnostic on the Horizon - Technology Networks